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ABSTRACT
Tumor-associated macrophages (TAMs) can constitute up to 50% of the tumor 
mass and have strong implications in tumor progression and metastasis. Macrophages 
are plastic and can polarize to various subtypes that differ in terms of surface receptor 
expression as well as cytokine and chemokine production and effector function. 
Conventionally, macrophages are grouped into two major subtypes: the classically 
activated M1 macrophages and the alternatively activated M2 macrophages. M1 
macrophages are pro-inflammatory, promote T helper (Th) 1 responses, and show 
tumoricidal activity, whereas M2 macrophages contribute to tissue repair and 
promote Th2 responses. Herein, we present a microfluidic system integrating tumor 
cell aggregates and subtypes of human monocyte-derived macrophages in a three-
dimensional hydrogel scaffold, in close co-culture with an endothelial monolayer to 
create an in vitro tumor microenvironment. This platform was utilized to study the 
role of individual subtypes of macrophages (M0, M1, M2a, M2b and M2c) in human 
lung adenocarcinoma (A549) aggregate dispersion, as a representation of epithelial-
mesenchymal transition (EMT). A significant difference was observed when M2a 
macrophages were in direct contact with or separated from A549 aggregates, suggesting 
a possible mechanism for proximity-induced, contact-dependent dissemination via ICAM-
1 and integrin β2 interactions. Indeed, M2a macrophages tended to infiltrate and release 
cells from carcinoma cell aggregates. These findings may help in the development of 
immunotherapies based on enhancing the tumor-suppressive properties of TAMs.
INTRODUCTION
Epithelial-mesenchymal transition (EMT) plays a 
critical role in the early stages of tumor dissemination [1]. 
During EMT, carcinoma cells lose their cell-cell junctions 
and acquire an invasive fibroblast-like morphology in 
the adjacent stroma. Subsequently, carcinoma cells may 
intravasate into blood and lymph vessels and disseminate 
to distant organs. Carcinoma cells undergoing EMT will 
acquire clonogenic and stem cell-like properties, escape 
immune surveillance and become refractory to treatment 
[2]. EMT is generally promoted via complex signaling 
networks involving tyrosine kinase receptors, growth 
factors and extracellular matrix (ECM) components [3, 
4]. Interestingly, it has been shown that tumor-associated 
macrophages (TAMs), which constitute the major 
component of infiltrated cells, contribute to EMT [5–7]. 
In fact, a tumor microenvironment of metastasis was 
observed to occur where there is a tripartite arrangement of 
an invasive cancer cell, a macrophage and an endothelial 
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cell [8, 9]. Despite recent studies on TAMs and other bone 
marrow-derived cells that promote EMT [6, 10, 11] and 
cancer metastasis [12–16], the regulatory mechanisms 
controlling TAM activation in response to a malignant 
environment have yet to be fully defined, as has their role 
in cancer.
In certain cases, TAMs exhibit an M1 phenotype, 
are pro-inflammatory, and have an anti-tumoral role, as 
shown in vitro for colon cancer [17, 18] and in patients 
with colorectal and gastric cancers [19, 20]. However, in 
numerous other cancers, such as breast [21], endometrial 
[22] and lung [6], macrophages acquire an alternative M2 
phenotype that promotes EMT invasion and metastasis, 
thus leading to a poor prognosis. M2 macrophages are 
further classified into M2a, M2b, and M2c based on the 
factors that promoted their polarization [23, 24].
Although significant progress has been made in 
identifying the chemokine repertoire that generates 
the diverse types of macrophages [25], their specific 
mechanisms of action in carcinoma cell dissemination 
remain unknown.
Here, we employed human lung adenocarcinoma 
(A549) cell aggregates to assess the role of distinct TAMs 
in inducing EMT and carcinoma cell dissemination. A 
three-dimensional (3D) microfluidic platform was created, 
integrating carcinoma cell aggregates, macrophages 
and human umbilical vein endothelial cells (HUVECs). 
Aside from enabling the dynamic visualization of 
carcinoma cell aggregate dispersion and the interaction 
between carcinoma cells and macrophages, this system 
provided significant advantages over other platforms 
with the opportunity for real-time monitoring and precise 
measurements of cell to cell distances [26]. Using 
this system, we found that M1 and M2b macrophages 
promoted the greatest dispersal of A549 carcinoma 
aggregates, regardless of their proximity to the aggregates. 
More interestingly, M2a macrophages promoted 
significant A549 carcinoma aggregate dispersal only 
when they were in contact with the carcinoma aggregates, 
and required integrins for allowing contact-dependent 
dissemination. Our results provide the first step towards 
a better understanding of allowing pathogenic roles of 
different macrophage subtypes and may aid in the design 
of novel cancer therapeutic treatments.
RESULTS
Stability of the 3D microfluidic-based tumor 
microenvironment
To investigate whether macrophages contribute to 
cancer cell EMT, we selected A549 lung carcinoma cells, 
as they exhibit a reversible EMT phenotype. In addition, 
TAMs have also been shown to promote EMT in non-
small cell lung cancer [6]. For this purpose, a microfluidic 
platform was designed with two parallel adjacent 
compartments containing 3D collagen matrices, flanked by 
channels for culture media (Figure 1A, 1B). In a previous 
study using a similar system [26], we demonstrated that 
HUVECs could promote carcinoma aggregate dispersal 
using a single collagen compartment. Here, we undertook a 
more integrative approach, where HUVECs were cultured 
in one of the media channels (Figure 1B, 1C) to mimic 
cancer cell proximity to a blood capillary, and we injected 
macrophages and A549 carcinoma aggregates into the 
collagen compartments. Human primary monocyte-derived 
macrophages (M0) were further polarized into either M1 or 
M2 (M2a, M2b, M2c) phenotypes before being introduced 
into the collagen compartment [24]. Two experimental 
configurations were set-up: (i) a “contact condition”, where 
macrophages and carcinoma aggregates were introduced 
and co-cultured within a single collagen compartment, 
(Figure 1B, left panel) and (ii) a “separated condition”, 
where the two cell types were placed in two separate but 
adjacent collagen compartments, with macrophages in the 
compartment next to the channel containing the HUVECs 
(Figure 1B, right panel). Such topographical arrangement 
partially reconstitutes an in vivo tumor microenvironment 
and thus provides an opportunity to examine the nature 
of macrophage/carcinoma cell interactions. Live and 
dead cell assays revealed good viability of M0 cells 
within the microfluidic device, even up to 36 h in culture 
(Supplementary Figure S2).
Consistently, immunostaining using CD80, a 
marker specific for M1, and CD209, a marker specific 
for M2a, showed that the various macrophages retained 
the expression of their respective markers after 36 h, 
even within the 3D collagen matrix in the presence of 
carcinoma aggregates and HUVECs (Figure 2).
Polarized macrophages differentially induce 
A549 carcinoma aggregate dispersal
To determine the effect of macrophages on A549 
carcinoma aggregate dispersal, the two cell types were 
cultured under “contact” or “separated” conditions, as 
described above. Figure 3A summarizes the normalized 
dispersion of aggregates when macrophages were grown 
under these conditions. Similar to what we had previously 
described, A549 aggregates exhibited greater dispersion 
in the presence of HUVECs (Ctrl in Figure 3A) versus 
the absence of HUVECs (Ctrl_0 in Figure 3A). When 
different subtypes of macrophages were included in the 
device with A549 cells and HUVECs, we found that M1 
and M2b macrophage subtypes specifically induced the 
greatest dispersion under both “contact” and “separated” 
conditions. Both subtypes induced a normalized dispersal 
measurement that was three to four times greater than 
that of the control (no macrophages). Unpolarized 
macrophages (M0) and M2c macrophages also promoted 
A549 aggregate dispersion, but the extent of dispersion 
under both conditions was lower than that observed 
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with the M1 and M2b macrophages. Interestingly, M2a 
macrophages under “contact” conditions showed increased 
aggregate dispersal similar to that of M1 macrophages, but 
the dispersal was significantly lower when M2a cells were 
grown under “separated” conditions (Figure 3A and 3B). 
Similar aggregate dispersions were also observed without 
HUVECs in the 3D culture (Supplementary Figure S4). 
Representative images of the aggregate dispersion in 
“contact” conditions for the other macrophage subtypes 
are in Supplementary Figure S3.
M2a macrophages preferentially migrate 
towards carcinoma aggregates
To capture the 3D dynamics of macrophage 
migration and carcinoma aggregate dispersion, time-
lapse images were taken every 10 min over a 12-h 
period under “contact” conditions (Supplementary 
Video S1). M2a macrophages located ≤50 μm from the 
carcinoma aggregate appeared to be the most motile, 
with an average migration speed of 7.7 μm/h. M2b and 
M2c motility varied between 5.2 and 5.8 μm/h, whereas 
M0 macrophages migrated at 5 μm/h; M1 macrophages 
exhibited the slowest speed of 3.6 μm/h (Figure 4C and 
Supplementary Video S1). In contrast, the motility of M2a 
macrophages located either ≥50 μm from the aggregates 
in the same compartment or seeded in the compartment 
adjacent to carcinoma aggregates was significantly lower 
(4–4.6 μm; Figure 4D). However, a reduction in speed was 
not observed for the other macrophage subtypes located 
at a distance ≥50 μm from the carcinoma aggregates 
(Supplementary Figure S5).
M2a macrophages within close proximity to the 
carcinoma aggregates were not only more motile, but 
they also exhibited directional migration towards the 
A549 aggregates (white arrows, top left, Figure 4B). In 
contrast, no directional migration was observed for the 
other macrophage subtypes (Figure 4A, Supplementary 
Figure S6). To confirm that M2a macrophages indeed 
exhibited directional migration, we further calculated the 
radial velocity of the cells (Supplementary Material), with 
negative values indicating macrophage migration towards 
the center of the A549 aggregate. When compared to M0 
and M1 macrophages, M2a macrophages showed a greater 
tendency to migrate towards the center of the carcinoma 
aggregate with an average radial velocity of –0.92 μm/h 
compared to –0.33 and –0.39 μm/h for M1 and M0 
macrophages, respectively (Figure 4E; Supplementary 
Video S1). Apart from migrating towards the aggregates, 
M2a macrophages were also observed to establish cell-cell 
Figure 1: Microfluidic co-culture platform to study the interactions between carcinoma aggregates and macrophages.  
A. Photograph of the polydimethyl siloxane (PDMS) device. B. Schematic images of an enlarged, isometric view of the channel layout 
showing the orientation of co-culturing carcinoma cell aggregates and endothelial cells (HUVECs), with macrophages either physically 
contacting (left panel; 1: media channel; 2: A549 aggregates and macrophages gel channel; 3. supporting gel channel; 4: HUVEC 
monolayer) or cultured under separated conditions (right panel; 1: media channel; 2: A549 aggregates gel channel; 3. macrophages gel 
channel; 4: HUVEC monolayer). C. HUVEC monolayers formed in the microfluidic channel. Green: GFP-HUVECs. D–F. E-cadherin 
immunocytochemical staining. E-cadherin expression of A549 aggregates at 0 h (D), E-cadherin expression of A549 aggregates in the 
absence (E) or presence (F) of macrophages at 36 h. Green: E-cadherin staining, red: mCherry A549 nuclei.
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contact with the aggregate. Following contact, A549 cells 
were found to detach from the aggregate.
M2a macrophages induce aggregate dispersion 
via a contact-mediated mechanism
To first assess whether M2a macrophages in contact 
with A549 aggregate promote EMT, immunocytochemical 
staining was performed on A549 aggregates in the presence 
or absence of M2a macrophages at 0 h and 36 h. The loss 
of expression of the epithelial marker E-cadherin was used 
to establish the occurrence of EMT (Figure 1D–1F, Green: 
E-cadherin staining, red: mCherry A549 nuclei). A549 
aggregates at 0 h showed clear E-cadherin expression on 
their surfaces (Figure 1D). E-cadherin expression remained 
up-regulated over 36 h in the absence of macrophages 
(Figure 1E). On the other hand, E-cadherin expression in 
A549 aggregates was down-regulated at 36 h in “contact” 
conditions with M2a macrophages (Figure 1F), suggesting 
that the EMT of A549 cancer cells was induced by the 
presence of M2a macrophages within close proximity.
To confirm whether aggregate dispersal in the 
presence of M2a macrophages was indeed dependent 
on cell-cell contact and to ascertain a role for adhesion in 
the process, we used flow cytometry to assess the surface 
expressions of CD11a, CD11b and CD11c integrins on 
macrophages; these proteins are expressed on leukocytes and 
interact with ICAM-1 on tumor cells (Figure 5A). We found 
that CD11a expression was highest on M2c macrophages, 
whereas CD11b and CD11c were highly expressed on both 
M2a and M2c macrophages; M2b macrophages showed the 
lowest expression of all three markers.
We next employed blocking antibodies against 
each integrin, as well as that against their collective 
β2-integrin binding partner, CD18, and tracked M2a 
macrophage migration and carcinoma aggregate 
dispersion by time-lapse imaging. We also assessed the 
involvement of ICAM-1, the ligand for these integrins, 
on A549 cancer cells using a neutralizing antibody. We 
found that specifically blocking CD11a, CD11b or CD18 
on M2a macrophages or ICAM-1 on A549 aggregates 
significantly inhibited carcinoma aggregate dissociation, 
whereas blocking CD11c had no effect (Figure 5B). 
Intriguingly, blocking CD11b or CD18 did not affect 
the migration speed of M2a macrophages (Figure 5D). 
Supplementary Video S2 demonstrates how blocking 
either CD11b or CD18 can prevent aggregate dissociation 
without altering macrophage motility. Thus, we show that 
M2a macrophages migrate toward the aggregates and 
promote aggregate dispersion through a contact-dependent 
mechanism (Figure 5C) that employs the interaction of 
integrin and ICAM-1.
Figure 2: Characterization of polarized macrophages. M0, M1 and M2a macrophages were immunostained for markers at either 
0 h or after culturing for 36 h in the microfluidic device in co-culture with A549 carcinoma aggregates: A. CD80 (M1 marker); B. CD209 
(M2a marker). Scale bars 50 μm.
(A) (B)
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M2a macrophages promote cancer cell migration 
in a transwell invasion assay
To validate the role of this integrin-mediated 
interaction of M2a macrophages with tumor cells, 
HUVECs were grown as monolayers on collagen-coated 
wells, recapitulating the three-cell type culture in the 
microfluidic device. Blocking CD18 on M2a macrophages 
significantly reduced the proportion of migrating A549 
cancer cells compared with that observed without the 
blocking antibody. We also found a reduced number of 
A549 cells that migrated in the presence of anti-CD11b 
Figure 3: A549 aggregates dispersion induced by various subtypes of macrophages. A. Quantitative measurement of aggregate 
dispersion at 36 h for macrophages under either “contact” or “separated” conditions. * indicates statistical calculations compared to no 
macrophage conditions, where *P < 0.05 and ****P < 0.0001. # indicates a statistical calculation between “contact” versus “separated” 
culture conditions, where #P < 0.01. Data are shown as a box plot with Tukey outliers. Ctrl_0 represents the control without HUVECs and 
without macrophages. Ctrl represents the control with HUVECs but without macrophages. B. Images of M2a inducing A549 aggregate 
dispersion under “contact” and “separated” conditions at 0 h or after culture for 36 h. Red: mCherry A549 nuclei. Scale bars 100 μm.
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blocking antibody; however, this reduction was not 
statistically significant (Figure 6A).
DISCUSSION
Tumors are characterized by a highly heterogeneous 
local microenvironment comprising various immune 
cells that affect cancer cell dissemination. TAM function 
varies depending on the tumor type and extent of tumor 
progression, and recent studies have emphasized a role for 
these macrophages in promoting tumor dissemination [18, 
27, 28]. Here, we investigated the influence of different 
macrophage subtypes on the EMT phenotype of lung 
carcinoma cells. We developed and demonstrated the 
capabilities of a 3D microfluidic assay to characterize 
the distinct roles played by different subtypes of macro-
phages on carcinoma aggregate dispersion, which is 
quantified as a metric of EMT. The three-cell culture 
system incorporated macrophages, lung adenocarcinoma 
A549 cells and HUVECs to partially mimic the in vivo 
microenvironment. Because macrophages can take on 
various phenotypes depending on the microenvironment, 
we differentiated human primary monocytes into different 
macrophage subtypes in vitro, namely M0, M1, M2a, M2b 
and M2c. Making use of our microfluidic system, we were 
able to position macrophages either in direct contact with 
or separated from carcinoma aggregates to establish their 
influence on the carcinoma cells.
Figure 4: Migration of macrophage subtypes. A. Migration direction (white arrows) of M0, M1, M2b, and M2c subtypes of 
macrophages under “contact” conditions with the carcinoma aggregates imaged at 6 h. B. Time-lapsed images of the M2a subtype under 
“contact” condition at specific times (top left). The migration direction (white arrows) of the M2a subtype that were ≤50 μm (M2a-
proximity; top right) or ≥50 μm (M2a-peripheral; bottom left) from the carcinoma aggregate under “contact” conditions or M2a cells under 
“separated” conditions (bottom right). Cells were imaged for 6 h. C. Migration speed of macrophages situated ≤50 μm from the carcinoma 
aggregates. D. Migration speed of M2a cells situated either ≤50 μm (M2a-proximity) or ≥50 μm (M2a-peripheral) from the carcinoma 
aggregates and grown under “separated” conditions. E. Radial velocity of M0, M1 and M2a subtypes under “contact” conditions. All data 
shown are mean ± SEM of at least three experiments. *P < 0.05, **P < 0.01. Green: DiO-labeled macrophages, red: mCherry A549 nuclei.
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Figure 5: Involvement of integrins in carcinoma aggregate dispersion by macrophages. A. Surface expression of CD11a, 
CD11b, and CD11c integrins on macrophage subtypes, as determined by FACS and expressed as mean fluorescence intensity (MFI). B. 
Normalized aggregate dispersion induced by M2a macrophages in the absence (–) or presence of various blocking antibodies at 12 h. 
*P <0.05 and **P < 0.01. C. Fluorescent image showing an M2a macrophage extending a projection (white arrow) as it attempts to 
dissociate a cancer cell from the aggregate. Green: DiO-labeled macrophages, red: mCherry A549 nuclei. D. Migration speed of M2a 
macrophages in the absence or presence of the indicated blocking antibodies. Data shown are mean ± SEM of three experiments.
Figure 6: Transwell migration assay of A549 carcinoma cells. A. Migration of A549 cells in the absence (No Mac) or presence 
of M2a macrophages without (–) or with the indicated blocking antibodies, measured after 12 h. Data are the mean ± SEM. *P < 0.05. B. 
Diagram showing the possible adhesion mechanism governing M2a-induced A549 aggregate dispersion via the interaction of ICAM-1 and 
β2 integrin.
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Among the macrophage subtypes investigated, M1 and 
M2b exhibited the strongest ability to induce EMT, regardless 
of whether they were in contact or in separate compartments 
(Figure 3A). Previous studies have demonstrated a strong link 
between inflammatory cytokines and EMT induction [29–32]. 
M1 macrophages are distinguished from other macrophage 
subtypes by their ability to secrete significant amounts of pro-
inflammatory cytokines, including IL-1β, IL-6 and TNFα [33]. 
M2 macrophages, in general, are characterized by their low 
production of pro-inflammatory cytokines, low levels of IL-
12 and IL-23, and a high expression of IL-10. M2b, however, 
is an exception, as these cells retain high levels of pro-
inflammatory cytokines concomitant with high levels of IL-10 
and CD86 but low levels of IL-12 and arginase-1 [34]. Thus, 
the most extensive carcinoma aggregate dispersion induced by 
M1 and M2b macrophage subtypes might be attributed to the 
pro-inflammatory cytokines that they secrete, which requires 
further investigation. Similar results were also observed when 
HUVECs were excluded from the 3D culture, suggesting that 
endothelial cells do not alter the response of these subtypes of 
macrophages, as M1 and M2b are still dominant in triggering 
dispersion (Supplementary Figures S3 and S4).
Most interestingly, M2a macrophages promoted 
significantly greater aggregate dispersion in “contact” 
rather than “separated” conditions (Figure 3B). We 
showed that M2a macrophages exhibited the fastest 
locomotion, especially when in close proximity to 
carcinoma aggregates, and they preferentially migrated 
towards the aggregates. This indicated that they may 
be responding to some soluble factors secreted by the 
carcinoma aggregates (Figure 4A and 4B). Numerous 
cancers express tumor-derived factors, such as CSF-
1 and CCL2, to recruit monocytes and promote 
their differentiation to macrophages in the tumor 
microenvironment [5, 25, 35–37]. For lung cancer, high 
intra-tumoral concentrations of CXCR2 ligands (CXCL1, 
CXCL5, and CXCL8) and type 2 cytokines IL-4, IL-5, 
IL-10, and IL-13 have been reported for non-small cell 
lung cancer [38, 39]. In our study, A549 aggregates 
may have been secreting one or more of these factors 
to specifically attract M2a macrophages since this is the 
macrophage subtype that expresses the CXCR2 receptor 
[40, 41].
ICAM-1 is a surface glycoprotein associated 
with numerous inflammatory and immune responses, 
mediating intercellular adhesion through binding to the 
β2 integrins: CD11a/CD18, CD11b/CD18 and CD11c/
CD18 [42–44]. Specifically, ICAM-1-CD11a/CD18 
interaction promotes the transendothelial migration of 
leukocytes from the capillary bed to the surrounding 
tissues. ICAM-1 also promotes the migration of other 
cell types, including cancer cells [45–47]. Using the 3D 
microfluidic assay, we showed that ICAM-1 was involved 
in carcinoma aggregate cell dissociation and migration 
(Figure 5B). Others have also shown a role for ICAM-
1 during tumor metastasis, particularly invasion and 
migration [47–49]. ICAM-1 could only be detected in 
carcinoma cells from a few patients with gastric cancer, 
whereas all of the metastatic carcinoma cells from 
peritoneal effusions exhibited high ICAM-1 expression. 
ICAM-1 also correlated significantly with the proportion 
of tumor-infiltrating leukocytes, including macrophages 
[46]. Among oral cancers, ICAM-1 is expressed 
predominantly at the invasive front of tongue squamous 
cell carcinoma (SCC) and positively correlated with 
invasion, lymph node metastasis and increased density 
of circulating cancer cells in the blood and lymphatic 
vessels [50]. Furthermore, ICAM-1 expression correlated 
with increased macrophage infiltration within the SCC 
tumor [50]. However, in these studies, the phenotypes of 
the macrophages that infiltrated the tumors were not well 
characterized. Usami et al. showed that the macrophages 
were positive for CD163 expression and proposed that 
they were M2 macrophages in general [50]. They further 
showed that CD11b on the macrophages was involved 
in the interaction with ICAM-1 on squamous carcinoma 
cells and promoted their adhesion.
In our study, we showed that blocking CD11b 
on M2a macrophages—but not other macrophage 
subtypes—inhibited aggregate dispersion (Figure 5B), 
suggesting that the interaction between macrophages 
and carcinoma cells via ICAM-1/β2 integrins is 
necessary for their dissociation from the aggregate, an 
indicator of EMT. Figure 6B proposes a mechanism for 
this dispersal and suggests that M2a macrophages are 
attracted by and directly interact with the carcinoma 
aggregate to down-regulate junctional complexes. This 
process requires the binding of CD11b/CD18 on M2a 
macrophages to ICAM-1 on A549 lung carcinoma cells. 
To our knowledge, this is the first report to show that 
the M2a macrophage subtype specifically promotes 
the dissociation carcinoma cells through a CD11b and 
ICAM-1 interaction. Our study thus emphasizes the 
unique role of the M2a macrophage subtype for tumor 
cell dispersion through direct cell-cell contact.
Recruitment of the M2 macrophage subtype into the 
tumor microenvironment has been observed in numerous 
cancers [41, 51–54]. A similar ability of M2 macrophages 
to promote cancer invasion and dissemination has also 
been reported in mouse models of breast and lung cancer 
[51, 52]. TAMs that have infiltrated non-small lung cancer 
promote EMT intra-tumorally in addition to inducing EMT 
at the invasive front [6]. In the tissue array of a cohort of 
491 patients, a positive correlation was observed between 
intra-tumoral macrophage prevalence, EMT marker 
expression, and tumor grade. In addition, the authors 
showed macrophage-derived TGFβ as the main inducer of 
the EMT phenotype [6]. Among the various macrophage 
subtypes, M2a and M2c could produce high levels of 
TGFβ. Although it is currently unclear how the interaction 
of M2a macrophages with the carcinoma aggregates via 
integrin/ICAM-1 can promote aggregate dissociation, it is 
likely that this interaction may act in synergy with secreted 
factors such as TGFβ to enhance EMT.
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In summary, we describe a microfluidic-based 
approach that identifies a possible mechanism for 
carcinoma-macrophage signaling in EMT in 3D cultures. 
The distinct role of each subtype of macrophage was 
analyzed, with M1 and M2b subtypes showing the 
greatest ability to induce dispersion, whereas M2a acts 
predominantly through a contact-dependent mechanism. 
Tumor-infiltrating macrophages are either a mixture of all 
subtypes or they constitute a spectrum of the phenotypes 
while still retaining partial functions of each subtype. The 
proportion of each subtype may vary from one cancer type 
to another, promoting different levels of dissemination. 
Different populations of hematopoietic cells in the tumor 
microenvironment may therefore be exploited to design 
immunotherapeutic approaches and anti-metastatic drug 
screening.
MATERIALS AND METHODS
Generation of A549-H2B-mCherry stable cells 
and cancer aggregate formation
Human lung adenocarcinoma cells (A549) (#CCL-
185; ATCC, Manassas, VA) were authenticated by the 
Centre for Translational Research and Diagnostics, 
National University of Singapore (November, 2014). 
A threshold of 80% was used to indicate authenticity, 
according to the standard ANSI/ATCC ASN-0002-2011. 
The authentication analysis was carried out using a 
Geneprint 10 system kit (Promega, Madison, WI) with 
capillary electrophoresis on the ABI 3130xl Genetic 
Analyzer (Life Technologies, Carlsbad, CA). STR 
marker calling was performed using Gene mapper V4.0 
software (Life Technologies) and Deutsche Sammlung 
von Mikroorganismen and Zellkulturen (DSMZ, www.
dsmz.de; includes ATCC, DSMZ, Riken, JCRB) and 
the Korean Cell Line Bank (KCLB, www.cellbank.snu.
ac.kr; for SNU) were assessed.
Cells were transfected with PH2B_mCherry_IRES_
puro2 plasmid (plasmid 21045, Addgene, Cambridge, MA) 
using FuGENE 6 (Roche, Basel, Switzerland). Transfected 
cells were cultured in the presence of puromycin (BD 
Biosciences, Franklin Lakes, NJ) for 48 h and FACS sorted 
for H2B-mCherry expression [26]. A549 aggregates were 
generated as previously described [56]. Briefly, A549 
cells were resuspended at 5 × 104 cells/ml in DMEM 
(Life Technologies) supplemented with 10% Fetal Bovine 
Serum (FBS (Life Technologies)) and 1% PenStrep (Life 
Technologies) and seeded into 90-mm culture dishes (VWR, 
Radnor, PA) that had been previously laser-ablated to produce 
a 100 × 100 array of microwells, pre-coated with 0.2% 
pluronic (Pluronic F108, BASF, Ludwigshafen, Germany) 
in PBS. Aggregates were retrieved after four days and sieved 
sequentially through 100-μm- and 40-μm-diameter cell 
strainers to yield aggregates of 40–100 μm in diameter. These 
samples were then enriched by centrifugation.
Differentiation and polarization of  
monocyte-derived macrophages
All blood samples and procedures were approved 
by the Domain Specific Review Board (DSRB), National 
Healthcare Group, Singapore (Reference code: 08-
352E). Written informed consent was given according to 
the principles expressed in the Declaration of Helsinki. 
Peripheral blood mononuclear cells were isolated from 
healthy donors’ buffy coats (National University Hospital 
Blood Donation Center, Singapore) by Ficoll-Paque 
density gradient centrifugation, and monocytes were 
positively selected using CD14 microbeads (Miltenyi 
Biotec, Auburn, CA). The purity, as determined by flow 
cytometry, and viability, as measured by trypan blue 
exclusion of monocytes, were 98.07% ± 1.7% and 98.77% 
± 0.8%, respectively.
Monocytes were maintained in Petri dishes in 
IMDM (Life Technologies) supplemented with 5% 
human serum and 100 ng/mL recombinant human 
M-CSF (Immunotools, Friesoythe, Germany) for five 
days to generate macrophages (hereafter labelled as 
M0). Macrophages were then either left untreated (M0) 
or polarized to M1 (20 ng/ml IFNγ(Roche) + 100 ng/
ml LPS (Sigma-Aldrich, St. Louis, MO)), M2a (20 ng/
ml IL-4 (Miltenyi Biotec)), M2b (human IgG (Jackson 
Immunoresearch Lab, West Grove, PA) coated wells + 
100 ng/ml LPS (Sigma-Aldrich)) or M2c (20 ng/ml IL-
10 (Miltenyi Biotec)) [24] for at least 24 h. Cell viability 
was assessed with a Live/Dead assay (Calcein/Ethidium 
Bromide (Life Technologies)).
Fabrication of microfluidic device and 
generation of the tumor microenvironment
Polydimethyl siloxane (PDMS (Dow Corning, 
Midland, MI)) was selected for fabrication of the tissue 
culture microfluidic device (Figure 1A). A PDMS replica 
was made by soft lithography from patterned wafers 
(SU-8). Coverslips were plasma bonded to the PDMS 
micropattern to create closed chambers. The device 
consisted of two inner adjacent channels (‘2’ and ‘3’; 
Figure 1B) and two outer media channels (‘1’ and ‘4’; 
Figure 1B).
HUVECs (Lonza, Basel, Switzerland) were cultured 
in EGM-2 endothelial cell growth media (Lonza) and 
grown as a confluent monolayer in channel ‘4’.
To create a “contact condition”, a type I collagen 
gel solution (2.5 mg/ml, pH 7.4) was introduced into 
channels ‘2’ and ‘3’. Approximately 30–40 tumor 
spheroids plus 2500–3000 macrophages in the collagen 
gel solution were introduced into channel 2 and allowed 
to polymerize via thermal cross-linking. The average 
distance between the HUVEC monolayer and carcinoma 
spheroids was 200 μm, which facilitated rapid cell-cell 
communication. DMEM was subsequently introduced 
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to the other empty media channel and changed on a 
24-h cycle. Cells within the collagen compartment 
were imaged by confocal microscopy (FluoView 1000, 
Olympus, Tokyo, Japan).
For the “separated condition”, 2500–3000 macro-
phages were mixed with the collagen gel solution and 
introduced into channel ‘3’, while 30–40 A549 carc i noma 
aggregates in collagen gel were injected into channel 
‘2’. All experiments were conducted in the pre sence of 
HUVECs unless otherwise stated.
Immunocytochemistry
To characterize the M1 and M2a macrophage 
phenotypes in the device, cells were stained with 
the specific surface markers CD80 (clone 2D10.4) 
(eBioscience, San Diego, CA) and CD209 (clone B-2) 
(Santa Cruz, Dallas, TX), respectively. To assess the 
EMT of A549 aggregates, they were stained with the 
epithelial marker E-cadherin (Life technologies). Briefly, 
cell culture medium was removed from the microfluidic 
device, and the channel(s) containing the cells were rinsed 
in cold PBS and then fixed in 4% paraformaldehyde 
(PFA) (Sigma-Aldrich) for 15 min at room temperature. 
Then, 0.1% Triton-X (Sigma-Aldrich) was added for 
10 min before blocking for 2 h at room temperature with 
PBS containing 5% BSA. After blocking, the samples 
were stained with CD80 (1:100), CD209 (1:50) or 
E-cadherin (1:100). The secondary antibody used was 
Alexa Fluor 488-conjugated anti-mouse IgG antibody 
(Life Technologies). Fluorescent images were obtained 
by confocal microscopy.
Image processing and analysis
Three-dimensional image stacks (100 μm range) 
of each tumor aggregate were acquired by confocal 
microscopy with a 20× objective lens (N.A. = 0.4). Images 
were acquired at 0 h and 36 h. Aggregate normalized 
dispersion was quantified using Imaris 6.0 software 
(Bitplane, Zurich, Switzerland) following a previously 
reported method [26]. For clarity, a detailed description 
can be found in the Supplementary Material.
For live-cell imaging, macrophages were stained 
with 5 μM green cell tracker CMFDA (Life Technologies). 
Macrophage migration was tracked by capturing confocal 
image stacks (4-μm slice thickness) every 10 min for up 
to 12 h with a 10 × (N.A. = 0.3) objective lens. Time-lapse 
confocal z-stacks of A549 aggregates and macrophages 
were acquired simultaneously to generate video clips (See 
Supplementary videos). The macrophage mean migration 
speed was calculated by Imaris from the recorded 
trajectory of an individual nucleus (Supplementary 
Material). The mean migration speeds were then averaged 
for all macrophages. Methods for calculating the 
macrophage radial velocity can be found in Supplementary 
Material and Supplementary Figure S1.
Flow cytometry
Polarized macrophages were washed once with 
PBS containing 2 mM EDTA and further incubated 
in PBS-EDTA at 37°C for 5 min. Cells were detached 
using a scraper and resuspended in FACS buffer (PBS 
containing 5% (vol/vol) human serum) and then stained 
with fluorochrome-conjugated antibodies for 15 min at 
room temperature. Labelled cells were washed once with 
FACS buffer and measured using an LSR Fortessa flow 
cytometer (BD Biosciences). Cells were also stained with 
isotype-matched antibodies to determine background 
staining. All data were analyzed using FlowJo software 
(Tree Star Inc., Ashland, OR).
Blocking experiments
Blocking antibodies (10 μg/ml) against CD11a 
(Thermo Fisher Scientific, Waltham, MA), CD11b 
(eBioscience, San Diego, CA), CD11c (R&D Systems, 
Minneapolis, MN), and CD18 (R&D Systems) were used 
on M2a macrophages, and an ICAM-1 blocking antibody 
(R&D Systems) was used on A549 aggregates. Cells were 
incubated with respective blocking antibodies for 1 h prior 
to mixing with the collagen gel solution and then injected 
into the microfluidic device. The blocking antibody was 
also added to culture media in the microfluidic lateral 
channels. Cells were cultured in DMEM supplemented 
with 10% FBS and 1% PenStrep that was inactivated by 
heating at 56°C for 45 min (decomplemented). Aggregate 
dispersion was evaluated at 0 h and 12 h and macrophage 
speed at 0 h and 6 h.
Transwell migration assay
Transwell plates (24-well, 8-μm pore size; Sigma-
Aldrich) were used to conduct the migration assay. The 
lower chambers of the plate were collagen-coated and filled 
with EGM-2 medium containing HUVECs. After 4 h, the 
medium in the lower chamber was replaced with fresh 
media. A549 cells and M2a macrophages either without 
blocking or pre-blocked with CD18 or CD11b were added 
to the upper chamber in decomplemented DMEM. The 
plate was incubated at 37°C with 5% CO2, and the cells 
were allowed to migrate for 12 h. Cells on the upper surface 
of the filters were removed using cotton swabs, whereas 
cells that migrated to the lower surface were fixed and 
imaged by confocal microscopy with a 10× objective lens 
(N.A. = 0.3). The percentage of migrated A549 cells with 
respect to the total number of seeded cells was calculated 
considering a total of 128 regions of interest.
Statistical analysis
All data are expressed as the mean ± S.E.M. An 
unpaired Student’s t-test was used to determine significance. 
Measurements were calculated by averaging the mean 
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values of at least three microfluidic devices, and each device 
represents one independent experiment. For integrin surface 
expression on macrophage subtypes, a one-way ANOVA 
with Tukey post-test was used to calculate significance.
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